Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Published:2017-05 Issue:5 Volume:4 Page:e225-e236
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Mesa Ruben A,Vannucchi Alessandro M,Mead Adam,Egyed Miklos,Szoke Anita,Suvorov Aleksandr,Jakucs Janos,Perkins Andrew,Prasad Ritam,Mayer Jiri,Demeter Judit,Ganly Peter,Singer Jack W,Zhou Huafeng,Dean James P,te Boekhorst Peter A,Nangalia Jyoti,Kiladjian Jean-Jacques,Harrison Claire N

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. Novel therapies for myelofibrosis;Stein;Leuk Lymphoma,2015

2. Therapy for myeloproliferative neoplasms: when, which agent, and how?;Geyer;Blood,2014

3. How I treat myelofibrosis;Tefferi;Blood,2011

4. How I treat myelofibrosis;Cervantes;Blood,2014

5. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report;Tefferi;Blood,2013

Cited by 240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Threonine Phosphorylation and the Yin and Yang of STAT1: Phosphorylation-Dependent Spectrum of STAT1 Functionality in Inflammatory Contexts;Cells;2024-09-12

2. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

3. Advances in Stem Cell Transplantation for Myelofibrosis;Current Hematologic Malignancy Reports;2024-09-06

4. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

5. Comparative efficacy and hematologic safety of different dosages of JAK inhibitors in the treatment of myelofibrosis: a network meta-analysis;Frontiers in Oncology;2024-08-30